The effect of joint of Shensong Yangxin Capsules and calcium dibutyryladenosine cyclophosphate on heart failure with concurrent arrhythmia and its impacts on serum MMP-9,BNP,and ALD
Li Zhiqiang
Zhang Yu
Niu Jingxia
Li Jie
Ji Bin
Abstract：Objective To investigate the therapeutic effect of joint of Shensong Yangxin Capsules and calcium dibu-tyryladenosine cyclophosphate on patients with heart failure with concurrent arrhythmia,and its impacts on serum matrix met-alloproteinase-9(MMP-9),B-type natriuretic peptide(BNP),and aldosterone(ALD).Methods From July 2022 to July 2024,124 patients with heart failure with concurrent arrhythmia treated in our hospital were regarded as the study subjects and in-cluded into the control group and the joint group,each with 62 patients.The control group adopted calcium dibutyryladenosine cyclophosphate,while the joint group adopted joint of Shensong Yangxin Capsules and calcium dibutyryladenosine cyclophos-phate.After treatment,the clinical therapeutic effect,cardiac function indicators[left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),and stroke volume(SV)],arrhythmia indicators[24h standard deviation of normal R-R interval(SDNN),24h continuous 5-minute standard deviation of normal R-R interval(SDANN),and root mean square of adjacent normal R-R interval differences(rMSSD)],24h electrocar-diogram parameters[PR interval,QTc interval,and 24h Q-T interval variability(24h QTV)],serum factors[matrix metallo-proteinase-9(MMP-9),B-type natriuretic peptide(BNP),aldosterone(ALD),interleukin-1 β(IL-1 β),IL-6,and high-sensitivity C-reactive protein(hs-CRP)],and safety were evaluated.Results The joint group showed clearly better therapeutic effects than the control group(P＜0.05).After treatment,the various indicators showed clear differences compared to before treatment(x2/P=5.962/0.015),and the joint group had clearly lower LVESD(t=3.617,P＜0.01),LVEDD(t=3.043,P=0.003),QTc(t=3.312,P=0.001),MMP-9(t=16.429,P＜0.01),BNP(t=16.866,P＜0.01),ALD(t=14.559,P＜0.01),IL-1β(t=6.148,P＜0.01),IL-6(t=11.977,P＜0.01),and hs-CRP(t=10.736,P＜0.01)than control group,and clearly higher LVEF(t=2.805,P=0.006),SV(t=6.345,P＜0.001),SDNN(t=10.585,P=0.006),SDANN(t=4.982,P＜0.001),rMSSD(t=10.392,P=0.003)、PR interval(t=3.592,P＜0.01),24h QTV(t=8.580,P＜0.01)than control group.In the safety analysis,there was no clear difference in adverse reactions between two groups(P＞0.05).Conclusion The joint of Shensong Yangxin Capsules and calci-um dibutyryladenosine cyclophosphate can clearly improve the clinical therapeutic effect of patients with heart failure with concurrent arrhythmia,promote the recovery of heart function,alleviate arrhythmia,inhibit inflammatory factors,and have high safety.
Keywords：Heart failureArrhythmiaShensong Yangxin CapsulesCalcium dibutyryladenosine cyclophosphateClinical therapeutic effect
Publication Date：2025-07-18
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 799-803,809 )